An observational study in Sepsis Syndrome and Systemic Inflammatory Response Syndrome, sponsored by Charles University, Czech Republic. Completed at 1 site in Czechia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-14.
Sponsored by Charles University, Czech Republic · Observational
Among 28 studies in Sepsis with a site in Czechia — 4 open to participants now, 5 under way, none of them phase 3. Sepsis · Czechia.
Among the 28 studies in Sepsis with a site in Czechia, this one is the 4th largest by enrollment of the 11 observational ones that give a count, is the only one that started in 2017, is one of 11 observational ones, and was the 12th registered.
2,417 studies on the registry are indexed under Sepsis; 542 are open to participants now.
Browse Sepsis studies →4 of the 28 studies in Sepsis with a site in Czechia are open now. Recruiting first, the newest first:
Charles University, Czech Republic · Sites in Czechia
Ages 18+
AstraZeneca · Sites in Czechia, United States, Argentina and 11 more countries
Ages 18–80
University Hospital Ostrava · Sites in Czechia
Ages 18+
Charles University, Czech Republic · Sites in Czechia
Ages 18+ · Healthy volunteers
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 318 Sepsis studies recruiting now, 213 (67%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 282 is above the median of 150 across 1,162 observational studies indexed under Sepsis.
Median enrollment 289 across the 16 interventional studies, 200 across the 11 observational. Of the 21 that completed or were terminated, 5 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 28 have an industry lead sponsor. The 10 most frequent:
Charles University, Czech Republic is the lead sponsor of 228 studies on the registry; 76 are open to participants now.
Charles University, Czech Republic has 4 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
1 of the studies in Sepsis with a site in Czechia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies in Sepsis with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to measure serum levels of myristic acid in septic patients and to compare them with myristic acid serum levels in patients with Systemic Inflammatory Response Syndrome of non infective etiology and in healthy volunteers. Furthermore, other biomarkers of sepsis are evaluated in comparison with microbiological findings detected either by standard hemocultures or by molecular biological methods.
Currently, there is an array of biomarkers potentially useful in diagnosis and prognosis in septic patients, either alone or in combination. Only a fraction of them is used in clinical practice. The reasons vary, low sensitivity or specificity is the main one, cost/benefit or difficult processing with the need of highly specialized laboratory to name the other.
Recent pilot study from Swedish authors (A.M.Kauppi et al.) published in 2016 showed high correlation of myristic acid levels in blood in patients with sepsis and bacteraemia. There was no other publication on this molecule in relation to sepsis before. Cambiaghi et al. observed its significant decrease in nonresponders to the treatment of septic shock.
Myristic acid is an organic acid of linear structure. Measurement of its level will be performed using gas chromatography linked with mass spectrometry.
2,417 studies on the registry are indexed under Sepsis; 542 are open to participants now.
This study's enrollment of 282 is above the median of 150 across 1,162 observational studies indexed under Sepsis.
Browse Sepsis studies →Charles University, Czech Republic is the lead sponsor of 228 studies on the registry; 76 are open to participants now.
Compared within Sepsis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Systemic Inflammatory Response Syndrome. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients admitted to ICU in study group, patients with Systemic Inflammatory Response Syndrome after surgery in SIRS group and subjects without systemic inflammation in control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with sepsis or septic shock admitted on Intensive Care Unit.
Patients with Systemic Inflammatory Response Syndrome non-infectious etiology.
Patients without systemic inflammation.
Serum concentration of Myristic Acid
Serum concentration of Myristic Acid in patients with sepsis or septic shock. Comparison with serum levels of Myristic Acid in patients with systemic inflammatory response syndrome non-infectious etiology and with subjects without systemic inflammation.
Time frame: 5 days
Correlation of serum concentration of procalcitonin with detection of microbial agents in blood
Comparison of procalcitonin concentration in serum with the results of blood culture using methods of classical microbiology and with molecular biological methods for the detection of microbial agents.
Time frame: 5 days
Plan to share: No
Ran from Oct 2017 to primary completion in Dec 2021, 50 months.
Of 492 non-industry observational studies under Sepsis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 58. This study's 50 months is above that.
Counting every sponsor, half of 544 studies reached it within 27 months; a quarter within 12 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charles University, Czech Republic →